Faculty Collaboration Database

Pancreatic Cells Are Resistant to KRASQ61L Expression due to Hyperactive ERK/MAPK Signaling and Apoptosis Induction. Cancer Res Commun 2025 Oct 01;5(10):1865-1878

Date

09/15/2025

Pubmed ID

40951926

Pubmed Central ID

PMC12541299

DOI

10.1158/2767-9764.CRC-25-0281

Scopus ID

2-s2.0-105019811183 (requires institutional sign-in at Scopus site)

Abstract

UNLABELLED: The RAS family of small GTPases is among the most frequently mutated gene families in human cancer. In pancreatic ductal adenocarcinoma (PDAC), ∼95% of cases harbor an activating KRAS mutation, primarily at codon 12, 13, or 61, with G12D being the most common overall (40%). In contrast, the KRASQ61L mutation, though constitutively active, is virtually absent in tumors of patients with PDAC. This suggests that KRASQ61L may engage in distinct, allele-specific signaling that limits its ability to drive tumorigenesis. Determining the mechanisms that limit the occurrence of this mutation will aid in our understanding of the critical KRAS effectors and pathways that drive tumorigenesis. To investigate these mechanisms, we utilized a tightly controlled doxycycline-inducible KRAS expression system in an isogenic, immortalized pancreatic cell line, enabling direct comparison of KRASQ61L with the common PDAC mutant KRASG12D. Using TurboID proximity labeling alongside RNA sequencing, we mapped early effector interactions and transcriptional responses, revealing that KRASQ61L induces greater hyperactivation of the ERK/MAPK pathway, resulting in increased nuclear translocation of ERK1/2. Finally, pancreatic cells are highly tolerant to overexpression of KRASG12D, but KRASQ61L overexpression leads to impaired proliferation and increased apoptosis. These findings provide experimental support for the long-standing "Goldilocks" model of oncogenic signaling, in which too much ERK/MAPK pathway activation is detrimental to tumorigenesis. Our work offers a mechanistic explanation for the relative absence of KRASQ61L in PDAC and contributes to our understanding of KRAS allele-specific vulnerabilities, which can inform future therapeutic strategies targeting KRAS-driven pancreatic cancer.

SIGNIFICANCE: This study demonstrates that KRASQ61L drives hyperactivation of ERK/MAPK signaling and triggers apoptosis, which limits the proliferation of pancreatic cells. These findings support a "Goldilocks" model of RAS signaling and suggest that strong hyperactivation of the ERK/MAPK pathway contributes to the selective absence of KRASQ61L in pancreatic tumorigenesis.

Author List

Burge RA, Bialousow L, McFall T, Bamonte L, Johnson G, Smith M, Vaena SG, Comte-Walters S, Ball LE, Berto S, O'Bryan JP, Hobbs GA

Author

Thomas Mcfall PhD Assistant Professor in the Biochemistry department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Apoptosis
Carcinoma, Pancreatic Ductal
Cell Line, Tumor
Gene Expression Regulation, Neoplastic
Humans
MAP Kinase Signaling System
Mutation
Pancreatic Neoplasms
Proto-Oncogene Proteins p21(ras)